Merck Serono, a division of Merck KGaA, and its partner Newron Pharmaceuticals, an Italian biopharmaceutical company, have initiated the Settle study, a six-month, randomized, double-blind, international Phase III
Electro-Optical Sciences, a medical device company, has entered into a committed equity financing facility with Kingsbridge Capital, a private investment group, in which Kingsbridge has committed to provide,
Nycomed has submitted a marketing authorization application to the European Medicines Agency for Daxas as a once-daily oral treatment for patients with chronic obstructive pulmonary disease associated with
Gilead Sciences, a biopharmaceutical company, has reported encouraging data from DAR-311, a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist darusentan as an add-on
Helix BioMed, a developer of peptide molecules, has reported a net loss of $919,743 or $0.04 per share for the first quarter of 2009, compared to a net
Novavax, a clinical-stage biopharmaceutical company, has reported a net loss of $8.35m, or $0.12 per share, for the first quarter of 2009 compared to a net loss of
Denmark-based healthcare company Novo Nordisk has reported encouraging results from the Titrate study showing that Levemir, taken once-daily, substantially lowered average blood sugar. Approximately 60% of patients taking
PARI Pharma, a division of PARI GmbH and a developer of aerosol therapies, has received an orphan drug designation from the European Commission based on a positive recommendation
Implicit Bioscience, a biopharmaceutical company, and CMC Icos Biologics, a contract development and manufacturing organization, have signed a manufacturing contract to support the next stage of development and
Sanofi-aventis has reported the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France. The investment in this new vaccine production facility, which is located close
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.